var data={"title":"Hematologic complications of malignancy: Anemia and bleeding","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Hematologic complications of malignancy: Anemia and bleeding</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/contributors\" class=\"contributor contributor_credentials\">Reed E Drews, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/contributors\" class=\"contributor contributor_credentials\">Stanley L Schrier, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/contributors\" class=\"contributor contributor_credentials\">Jennifer S Tirnauer, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 30, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anemia frequently complicates the course of cancer. While anemia may be a presenting sign of malignancy, it may also be a consequence of a patient's antineoplastic therapy or progressive disease. Since anemia is a frequent cause of fatigue and fatigue ranks as the most common symptom plaguing cancer patients and limiting their daily routines, recognizing anemia and its causes is important for identifying appropriate interventions that may improve the cancer patient's quality of life [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/1-5\" class=\"abstract_t\">1-5</a>]. (See <a href=\"topic.htm?path=cancer-related-fatigue-prevalence-screening-and-clinical-assessment#H11\" class=\"medical medical_review\">&quot;Cancer-related fatigue: Prevalence, screening and clinical assessment&quot;, section on 'Anemia'</a> and <a href=\"topic.htm?path=cancer-related-fatigue-treatment#H3\" class=\"medical medical_review\">&quot;Cancer-related fatigue: Treatment&quot;, section on 'Anemic patients'</a>.)</p><p>This review will discuss those causes of anemia that are of specific relevance in patients with neoplastic disease. A general discussion of anemia and treatment of anemia in patients with malignancy is presented separately. (See <a href=\"topic.htm?path=approach-to-the-adult-with-anemia\" class=\"medical medical_review\">&quot;Approach to the adult with anemia&quot;</a> and <a href=\"topic.htm?path=anemia-in-adults-due-to-decreased-red-blood-cell-production\" class=\"medical medical_review\">&quot;Anemia in adults due to decreased red blood cell production&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-hemolytic-anemia-in-the-adult\" class=\"medical medical_review\">&quot;Diagnosis of hemolytic anemia in the adult&quot;</a> and <a href=\"topic.htm?path=role-of-erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-patients-with-cancer\" class=\"medical medical_review\">&quot;Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8168494\"><span class=\"h1\">OVERVIEW</span></p><p class=\"headingAnchor\" id=\"H8168638\"><span class=\"h2\">Mechanisms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As with anemias in general, three broad categories should be considered when assessing causes of anemia in patients with malignancies. (See <a href=\"topic.htm?path=approach-to-the-adult-with-anemia#H15\" class=\"medical medical_review\">&quot;Approach to the adult with anemia&quot;, section on 'Causes of anemia'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Red blood cell (RBC) losses from the body (blood loss anemia)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased RBC destruction (hemolytic anemia)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decreased RBC production (hypoproliferative anemia)</p><p/><p>While one or more of these three mechanisms must be responsible when anemia is present, some causes are relatively specific for patients with malignancy. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Direct effects of the neoplasm</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An effect of a product of the neoplasm</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Effects of treatment directed against the neoplasm</p><p/><p class=\"headingAnchor\" id=\"H8168787\"><span class=\"h2\">Generalized bleeding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with malignancy may have bleeding <span class=\"nowrap\">and/or</span> anemia due to a wide number of causes, which will be discussed in depth in the following sections. In addition to bleeding from the tumor itself, causes for generalized bleeding in the patient with malignancy that should be kept in mind include [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/6\" class=\"abstract_t\">6</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thrombocytopenia-associated bleeding from treatment-associated bone marrow suppression. (See <a href=\"#H18\" class=\"local\">'Anemia from effects of cancer treatment'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tumor-associated immune thrombocytopenia. (See <a href=\"topic.htm?path=overview-of-the-complications-of-chronic-lymphocytic-leukemia#H20\" class=\"medical medical_review\">&quot;Overview of the complications of chronic lymphocytic leukemia&quot;, section on 'Thrombocytopenia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Disseminated intravascular coagulation with coagulopathy-associated bleeding. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults#H7833673\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;, section on 'Laboratory abnormalities'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acquired inhibitors of coagulation (eg, acquired von Willebrand disease, acquired factor VIII deficiency). (See <a href=\"topic.htm?path=classification-and-pathophysiology-of-von-willebrand-disease#H13\" class=\"medical medical_review\">&quot;Classification and pathophysiology of von Willebrand disease&quot;, section on 'Acquired von Willebrand syndrome'</a> and <a href=\"topic.htm?path=acquired-inhibitors-of-coagulation#H3\" class=\"medical medical_review\">&quot;Acquired inhibitors of coagulation&quot;, section on 'Epidemiology'</a> and <a href=\"topic.htm?path=acquired-von-willebrand-syndrome\" class=\"medical medical_review\">&quot;Acquired von Willebrand syndrome&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bleeding secondary to the use of therapeutic or prophylactic anticoagulation. (See <a href=\"topic.htm?path=treatment-of-venous-thromboembolism-in-patients-with-malignancy#H3\" class=\"medical medical_review\">&quot;Treatment of venous thromboembolism in patients with malignancy&quot;, section on 'Anticoagulation therapy'</a> and <a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer#H10\" class=\"medical medical_review\">&quot;Risk and prevention of venous thromboembolism in adults with cancer&quot;, section on 'Prevention of VTE in patients with cancer'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pre-existing coagulation or bleeding disorders (eg, von Willebrand disease, peptic ulcer disease). (See <a href=\"topic.htm?path=approach-to-the-adult-patient-with-a-bleeding-diathesis\" class=\"medical medical_review\">&quot;Approach to the adult patient with a bleeding diathesis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H8168618\"><span class=\"h2\">Presence of multiple causes of anemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple factors may contribute to the development of anemia in the cancer patient. In determining which factors may be responsible, it is important to correlate patients' clinical histories and physical exam findings with laboratory observations, realizing that more than one contributor may underlie the development of anemia. (See <a href=\"topic.htm?path=approach-to-the-adult-with-anemia#H50\" class=\"medical medical_review\">&quot;Approach to the adult with anemia&quot;, section on 'Multiple causes of anemia'</a>.)</p><p>As an example, a large prospective observational study evaluated multiple factors leading to the development of anemia in 888 patients with cancer, <strong>prior</strong> to the institution of any cancer treatment. Observations included the following [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/7\" class=\"abstract_t\">7</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sixty-three percent of the patients in this study were anemic, with the incidence of anemia increasing with increasing cancer stage and decreasing Karnofsky performance status (<a href=\"image.htm?imageKey=ONC%2F57945\" class=\"graphic graphic_table graphicRef57945 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemoglobin concentration was inversely correlated with the levels of inflammatory markers, hepcidin, ferritin, erythropoietin, reactive oxygen species, and the modified Glasgow Prognostic Score [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/8\" class=\"abstract_t\">8</a>], and positively correlated with leptin, albumin, cholesterol, and antioxidant enzymes.</p><p/><p>It was concluded that cancer-related anemia is a multifactorial problem, with immune, nutritional, and metabolic components affecting its severity.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h2\">WHO grading of anemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>According to the <span class=\"nowrap\">WHO/National</span> Cancer Institute, normal values for hemoglobin (Hgb) are 12 to 16 <span class=\"nowrap\">g/dL</span> in women and 14 to 18 <span class=\"nowrap\">g/dL</span> in men [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/9\" class=\"abstract_t\">9</a>]. The WHO grading of anemia is defined, as follows [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/10\" class=\"abstract_t\">10</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mild (Grade 1) &ndash; Hgb from 10 <span class=\"nowrap\">g/dL</span> to the lower limit of normal</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Moderate (Grade 2) &ndash; Hgb 8.0 to 9.9 <span class=\"nowrap\">g/dL</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe (Grade 3) &ndash; Hgb 6.5 to 7.9 <span class=\"nowrap\">g/dL</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Life-threatening (Grade 4) &ndash; Hgb &lt;6.5 <span class=\"nowrap\">g/dL</span></p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ANEMIA FROM DIRECT EFFECTS OF NEOPLASMS</span></p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">External bleeding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intraluminal neoplasms (eg, malignancies arising from or metastatic to the gastrointestinal or genitourinary tract) may bleed, producing blood loss anemia. Accordingly, when evaluating cancer patients who have anemia, stool and urine samples should be examined for the presence of blood. (See <a href=\"topic.htm?path=evaluation-of-occult-gastrointestinal-bleeding\" class=\"medical medical_review\">&quot;Evaluation of occult gastrointestinal bleeding&quot;</a>.)</p><p>While the patient's hemoglobin, hematocrit, and red blood cell (RBC) indices may be normal in the early stages of blood loss, persistent bleeding will ultimately result in the laboratory findings of iron deficiency when the patient's iron stores become depleted. This is usually reached in men when total blood loss exceeds 1200 mL and in women at approximately 600 mL. (See <a href=\"topic.htm?path=approach-to-the-adult-with-anemia#H19\" class=\"medical medical_review\">&quot;Approach to the adult with anemia&quot;, section on 'Blood loss'</a> and <a href=\"topic.htm?path=causes-and-diagnosis-of-iron-deficiency-and-iron-deficiency-anemia-in-adults#H23\" class=\"medical medical_review\">&quot;Causes and diagnosis of iron deficiency and iron deficiency anemia in adults&quot;, section on 'Diagnostic evaluation'</a>.)</p><p>Decreased concentrations of serum ferritin, reflecting deficient stores of iron, may be present. In addition, microcytic, hypochromic RBCs may be evident on review of peripheral blood smears (<a href=\"image.htm?imageKey=HEME%2F64267\" class=\"graphic graphic_picture graphicRef64267 \">picture 1</a>). A progressive decrease over time in RBC mean corpuscular volume (MCV), <span class=\"nowrap\">and/or</span> mean corpuscular hemoglobin (MCH) is another clue that iron deficiency may be developing. (See <a href=\"topic.htm?path=causes-and-diagnosis-of-iron-deficiency-and-iron-deficiency-anemia-in-adults#H3387816535\" class=\"medical medical_review\">&quot;Causes and diagnosis of iron deficiency and iron deficiency anemia in adults&quot;, section on 'Findings on CBC'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Impaired absorption of nutrients</span></p><p class=\"headingAnchor\" id=\"H13284596\"><span class=\"h3\">Iron deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>While iron deficiency most commonly arises from bleeding, it may occasionally result from impaired iron absorption. Iron malabsorption should be considered in patients with iron deficiency who do not respond to treatment with oral iron <span class=\"nowrap\">and/or</span> whose malignancies involve the mucosa of the duodenum <span class=\"nowrap\">and/or</span> upper jejunum, the sites of maximal iron absorption. (See <a href=\"topic.htm?path=regulation-of-iron-balance#H21\" class=\"medical medical_review\">&quot;Regulation of iron balance&quot;, section on 'Intestinal iron absorption'</a>.)</p><p>This effect can be direct, as in gastrointestinal lymphoma [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/11\" class=\"abstract_t\">11</a>], or indirect, as in amyloidosis from multiple myeloma [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/12\" class=\"abstract_t\">12</a>]. Iron malabsorption may also arise in patients who have had certain surgical operations, for example, partial or total gastrectomy resulting in achlorhydria, gastric dumping, or afferent (blind) loop syndromes with or without bacterial overgrowth [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/13-15\" class=\"abstract_t\">13-15</a>]. If iron deficiency anemia is present and bleeding as a source of iron loss is not evident, disorders of impaired iron absorption should be considered. In such cases, an oral iron absorption test may be helpful [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/11,16\" class=\"abstract_t\">11,16</a>] Intravenous iron may be required in such circumstances. (See <a href=\"topic.htm?path=treatment-of-iron-deficiency-anemia-in-adults#H14\" class=\"medical medical_review\">&quot;Treatment of iron deficiency anemia in adults&quot;, section on 'Intravenous iron'</a>.)</p><p class=\"headingAnchor\" id=\"H13284602\"><span class=\"h3\">B12 deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgical removal of tumors involving the stomach (the source of intrinsic factor) or terminal ileum (the site of B12 absorption) may result in B12 deficiency. However, because body stores of B12 in the liver may be extensive, B12 deficiency may take years to develop following such surgery. (See <a href=\"topic.htm?path=causes-and-pathophysiology-of-vitamin-b12-and-folate-deficiencies#H1977335754\" class=\"medical medical_review\">&quot;Causes and pathophysiology of vitamin B12 and folate deficiencies&quot;, section on 'Causes of vitamin B12 deficiency'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Internal bleeding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Occasionally, there may be significant bleeding into the body of the tumor, resulting in acute anemia. Most patients suffering this complication have hepatocellular carcinoma, and spontaneous liver rupture can arise with catastrophic consequences [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/17,18\" class=\"abstract_t\">17,18</a>]. Other malignancies associated with hemorrhage into the tumor, with risk of massive internal bleeding include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malignant hepatic epithelioid hemangioendothelioma [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/17\" class=\"abstract_t\">17</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Peliosis hepatis and liver cell adenomas [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/17,19\" class=\"abstract_t\">17,19</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Liver metastases, especially from cutaneous or ocular melanomas [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/20\" class=\"abstract_t\">20</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Splenic hemangiosarcomas [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/21\" class=\"abstract_t\">21</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stromal ovarian tumors or cancers metastatic to the ovary [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/22,23\" class=\"abstract_t\">22,23</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Retroperitoneal tumors with retroperitoneal hemorrhage [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/24-27\" class=\"abstract_t\">24-27</a>]</p><p/><p>Cavernous hemangioma is the most common benign tumor involving the liver. While the vast majority of these are small and asymptomatic, some can result in spontaneous fatal hemorrhage [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/28\" class=\"abstract_t\">28</a>]. Surgery and angiography with embolization are preferred approaches to management of patients with intratumor bleeding and rupture [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/17,28,29\" class=\"abstract_t\">17,28,29</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Other causes of bleeding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Not all bleeding episodes will be related to direct effects of the patient's malignancy, and other causes (for example, peptic ulcer disease and mucosal erosive disease) should be considered. Additionally, coagulopathies can enhance bleeding risk, and correlation of patients' hemorrhagic tendencies should be made with laboratory tests assessing the patient's hemostatic competencies (eg, platelet count, prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen). (See <a href=\"topic.htm?path=approach-to-the-adult-patient-with-a-bleeding-diathesis\" class=\"medical medical_review\">&quot;Approach to the adult patient with a bleeding diathesis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Hemophagocytosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hemophagocytosis is characterized by ingestion of RBCs by macrophages or cancer cells. While the hemophagocytic syndrome is most commonly seen in association with infection, particularly Epstein-Barr virus (EBV) infection, this disorder can complicate certain malignancies, producing anemia in the absence of documented infection [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/30\" class=\"abstract_t\">30</a>]. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-hemophagocytic-lymphohistiocytosis#H550080\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of hemophagocytic lymphohistiocytosis&quot;, section on 'Malignancy'</a>.)</p><p>Cancer types most commonly associated with this syndrome are the leukemias and the lymphomas. The latter are usually of T cell lineage, although NK cell, B cell, and myeloid proliferations causing hemophagocytosis have also been described [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/31-33\" class=\"abstract_t\">31-33</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-subcutaneous-panniculitis-like-t-cell-lymphoma#H3\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma&quot;, section on 'Clinical presentation'</a> and <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-extranodal-nk-t-cell-lymphoma-nasal-type#H4\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type&quot;, section on 'Clinical features'</a>.)</p><p>Interferon-gamma and monocyte-colony stimulating factor (M-CSF) levels may be elevated, and levels of such cytokines and growth factors that stimulate macrophage activation may correlate significantly with the degree of clinical manifestations and laboratory data [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/32\" class=\"abstract_t\">32</a>]. Rarely, solid tumors demonstrate hemophagocytosis [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/34,35\" class=\"abstract_t\">34,35</a>]. Detection of hemophagocytosis is generally made by bone marrow aspiration and biopsy, which reveals macrophages or cancer cells with ingested whole RBCs. Therapy is treatment of the underlying malignancy, but prognosis is poor. (See <a href=\"topic.htm?path=evaluation-of-bone-marrow-aspirate-smears#H4378025\" class=\"medical medical_review\">&quot;Evaluation of bone marrow aspirate smears&quot;, section on 'Macrophages (histiocytes) with ingested cells or debris'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Bone marrow replacement</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Leukemias, lymphomas, and plasma cell dyscrasias are hematopoietic malignancies that commonly involve bone marrow, supplanting normal hematopoiesis and resulting in myelophthisis with anemia and other cytopenias. Solid tumors can also produce anemia by involving the bone marrow space through metastasis.</p><p>Disruption of the bone marrow microenvironment produces a leukoerythroblastic blood picture. This process is defined by the appearance of immature granulocytes, tear drop RBCs, and nucleated RBCs in peripheral blood (<a href=\"image.htm?imageKey=HEME%2F55274%7EHEME%2F68110\" class=\"graphic graphic_picture graphicRef55274 graphicRef68110 \">picture 2A-B</a>). Detection of this finding on review of a patient's peripheral blood smear should alert the clinician to the possibility of myelophthisic disease. (See <a href=\"topic.htm?path=anemia-in-adults-due-to-decreased-red-blood-cell-production#H12\" class=\"medical medical_review\">&quot;Anemia in adults due to decreased red blood cell production&quot;, section on 'Leukoerythroblastic anemia'</a>.)</p><p>While leukoerythroblastosis can arise from hematopoietic malignancies [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/36\" class=\"abstract_t\">36</a>], it is more commonly seen in patients with tumors metastatic to bone marrow (<a href=\"image.htm?imageKey=HEME%2F70576\" class=\"graphic graphic_picture graphicRef70576 \">picture 3</a>) [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/37\" class=\"abstract_t\">37</a>]. In this instance, myelofibrosis and hepatosplenic extramedullary hematopoiesis appear to be important to the pathogenesis of the leukoerythroblastosis [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/38,39\" class=\"abstract_t\">38,39</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The myeloproliferative neoplasms are commonly associated with a leukoerythroblastic blood picture (eg, post-polycythemia myelofibrosis, post-essential thrombocythemia myelofibrosis, and primary myelofibrosis). (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-primary-myelofibrosis#H3141935\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of primary myelofibrosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Solid tumor types most commonly resulting in this disorder are prostatic and gastric carcinomas [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/38,40\" class=\"abstract_t\">38,40</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-primary-myelofibrosis#H13251881\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of primary myelofibrosis&quot;, section on 'Non-hematologic conditions'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">ANEMIA FROM PRODUCTS OF NEOPLASMS</span></p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Amyloid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Amyloid, either primary (AL) or secondary (AA), may deposit in a variety of organs including bone. While large bone deposits of amyloid (amyloidomas) may be seen, producing osteolytic lesions and pathologic fractures [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/41\" class=\"abstract_t\">41</a>], extensive replacement of bone marrow by amyloid is rare. Hence, anemia and other cytopenias are not a prominent feature of amyloidosis unless renal failure or coagulopathy is present. (See <a href=\"topic.htm?path=clinical-presentation-laboratory-manifestations-and-diagnosis-of-immunoglobulin-light-chain-al-amyloidosis#H1664672\" class=\"medical medical_review\">&quot;Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis&quot;, section on 'Systemic presentations'</a>.)</p><p>While disorders causing secondary (AA) amyloid are chiefly chronic inflammatory and infectious diseases, malignant diseases giving rise to AA amyloid have been reported, including Hodgkin lymphoma, non-Hodgkin lymphoma, macroglobulinemia, renal cell carcinoma, and hepatocellular carcinoma [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/42-48\" class=\"abstract_t\">42-48</a>]. (See <a href=\"topic.htm?path=overview-of-amyloidosis#H16\" class=\"medical medical_review\">&quot;Overview of amyloidosis&quot;, section on 'Hematologic abnormalities'</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Hemolysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hemolysis, defined here as a shortening of RBC survival to less than 100 days, may occur in various malignancies. Two different mechanisms may be involved:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Production of autoantibodies that recognize red cell membrane antigens and cause an autoimmune hemolytic anemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Microangiopathic changes, which cause fragmentation hemolysis</p><p/><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Autoimmune hemolytic anemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Autoimmune hemolytic anemia (AIHA) is usually associated with the presence of immunoglobulin (IgG) or complement (C3d) on the surface of circulating RBCs, as detected by the direct antiglobulin (Coombs) test. (See <a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-warm-agglutinins-and-drugs#H3\" class=\"medical medical_review\">&quot;Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs&quot;, section on 'Antibody detection: the direct Coombs test'</a>.)</p><p>The presence of spherocytic RBCs on the peripheral smear, along with increased serum concentrations of indirect bilirubin and lactate dehydrogenase (LDH) and reduced concentrations of haptoglobin are the hallmark findings (<a href=\"image.htm?imageKey=HEME%2F70611\" class=\"graphic graphic_picture graphicRef70611 \">picture 4</a>). While cancer-associated AIHA is most frequently noted in patients with chronic lymphocytic leukemia (CLL), other associated tumors include non-Hodgkin lymphoma, Hodgkin lymphoma, carcinomas, multiple myeloma, Waldenstr&ouml;m macroglobulinemia, acute myeloid leukemia, angioimmunoblastic T cell lymphoma (formerly termed angioimmunoblastic lymphadenopathy with dysproteinemia), acute lymphoblastic leukemia, and myelodysplasia [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/49,50\" class=\"abstract_t\">49,50</a>].</p><p>While the majority of AIHAs are due to warm-reacting antibodies, certain malignancies may be associated with cold-reacting antibodies. These include CLL, Waldenstr&ouml;m macroglobulinemia, and the lymphomas. (See <a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-cold-agglutinin-disease#H8\" class=\"medical medical_review\">&quot;Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease&quot;, section on 'Association with malignancy'</a>.)</p><p>Treatment of cancer-associated AIHA is directed at the underlying malignancy. Of note, AIHA may be exacerbated by <a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">fludarabine</a> and other purine nucleoside analogs used in the treatment of certain indolent lymphoproliferative disorders such as CLL and follicular lymphoma [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/51-53\" class=\"abstract_t\">51-53</a>]. The mechanism is unclear, but may be related to altered T cell immunity and dysregulation of B cells, since fludarabine induces a decline in CD4 cells [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/54\" class=\"abstract_t\">54</a>]. (See <a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-warm-agglutinins-and-drugs#H11\" class=\"medical medical_review\">&quot;Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs&quot;, section on 'Genesis of antibody production'</a> and <a href=\"topic.htm?path=autoimmune-complications-following-purine-analog-therapy#H3\" class=\"medical medical_review\">&quot;Autoimmune complications following purine analog therapy&quot;, section on 'Autoimmune hemolytic anemia'</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Microangiopathic hemolysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In microangiopathic hemolytic anemia (MAHA), Coombs testing is negative, and schistocytes (RBC fragments) are the hallmark peripheral blood smear finding (<a href=\"image.htm?imageKey=HEME%2F70851\" class=\"graphic graphic_picture graphicRef70851 \">picture 5</a>). MAHA in malignancy may be a consequence of thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), a drug-induced thrombotic microangiopathy (DITMA) or disseminated intravascular coagulation (DIC). (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults#H255175\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;, section on 'Causes of DIC'</a> and <a href=\"topic.htm?path=pathophysiology-of-acquired-ttp-and-other-primary-thrombotic-microangiopathies-tmas#H2626376\" class=\"medical medical_review\">&quot;Pathophysiology of acquired TTP and other primary thrombotic microangiopathies (TMAs)&quot;, section on 'Hematologic findings'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>TTP, HUS, DITMA</strong> &ndash; Patients with TTP, HUS, or DITMA present with thrombocytopenia and a microangiopathic blood smear but, since there is primary platelet consumption, levels of the coagulation components are usually normal and there is little or no prolongation of the prothrombin time (PT) or activated partial thromboplastin time (aPTT). (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults#H13563746\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;, section on 'DIC versus other TMAs'</a>.)</p><p/><p class=\"bulletIndent1\">Measurement of fibrinogen and D-dimer also helps to clarify the situation, since these tests are generally normal in TTP, HUS, or DITMA and abnormal in DIC. (See <a href=\"topic.htm?path=approach-to-the-patient-with-suspected-ttp-hus-or-other-thrombotic-microangiopathy-tma#H16673009\" class=\"medical medical_review\">&quot;Approach to the patient with suspected TTP, HUS, or other thrombotic microangiopathy (TMA)&quot;, section on 'Initial evaluation (all patients)'</a> and <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>DIC</strong> &ndash; In DIC, the primary findings are those of depletion of coagulation factors along with increases in fibrin degradation products and D-dimer (<a href=\"image.htm?imageKey=HEME%2F63831\" class=\"graphic graphic_table graphicRef63831 \">table 2</a>). Peripheral blood schistocytes are generally few in number, whereas in TTP they are often plentiful and readily detectable on review of peripheral blood smears. Accordingly, serum LDH levels due to hemolysis and tissue ischemia are generally more strikingly elevated in TTP than in DIC, often reaching levels higher than 1000 international <span class=\"nowrap\">units/L</span> [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/55\" class=\"abstract_t\">55</a>]. Similarly, peripheral blood nucleated RBCs due to stress erythropoiesis are more common with TTP than with DIC, unless leukoerythroblastosis from myelophthisis is present as a confounding factor. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;</a>.)</p><p/><p>Most patients with cancer-related MAHA have already been diagnosed with cancer, although it can occasionally be a presenting sign of malignancy [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/56\" class=\"abstract_t\">56</a>]. However, many disorders other than cancer may trigger MAHA, particularly infection-associated sepsis and DIC [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/57\" class=\"abstract_t\">57</a>]. Hence, implicating cancer as the cause of MAHA requires exclusion of these other causes.</p><p>Both solid tumors and hematologic malignancies may give rise to MAHA [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/58\" class=\"abstract_t\">58</a>]. However, in contrast to leukemia-associated MAHA, which is generally due to DIC with risk of hemorrhage from consumptive coagulopathy (as in acute promyelocytic leukemia), solid tumor-associated MAHA is generally thrombotic, with an increased risk for thrombotic complications and renal failure. The solid tumors most commonly associated with MAHA are mucinous adenocarcinomas (eg, gastric, breast, pancreas, prostate, lung) [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/59-61\" class=\"abstract_t\">59-61</a>]. (See <a href=\"topic.htm?path=pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy#H370300336\" class=\"medical medical_review\">&quot;Pathogenesis of the hypercoagulable state associated with malignancy&quot;, section on 'Mechanisms underlying the hypercoagulable state'</a>.)</p><p>MAHA may also arise as a consequence of antineoplastic therapy or hematopoietic cell transplantation. The implicated drugs, mechanism, presentation, and management are discussed in detail separately. (See <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H516159\"><span class=\"h4\">Mechanisms</span></p><p class=\"headingAnchor\" id=\"H516165\"><span class=\"h5\">DIC</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mechanisms responsible for cancer-triggered DIC are uncertain. For example, tissue factor, the activator of factor VII, has been shown to be expressed on the surface of certain tumor cells [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/62\" class=\"abstract_t\">62</a>] as well as on circulating procoagulant microparticles in patients with malignancy [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/63,64\" class=\"abstract_t\">63,64</a>]. In addition, tumor necrosis factor and interleukin-6, proinflammatory cytokines associated with the malignant state, may dysregulate anticoagulant and antifibrinolytic mechanisms [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/65,66\" class=\"abstract_t\">65,66</a>]. (See <a href=\"topic.htm?path=pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy#H3\" class=\"medical medical_review\">&quot;Pathogenesis of the hypercoagulable state associated with malignancy&quot;, section on 'Tissue factor'</a>.)</p><p>Cancer procoagulant (CP) is a calcium-dependent cysteine protease, which has been found in malignant and fetal tissue, but not normally differentiated tissue. It activates factor X directly, independent of the tissue <span class=\"nowrap\">factor/factor</span> VIIa complex. CP is present in extracts of cells obtained from patients with acute promyelocytic leukemia (APL), malignant melanoma, and cancers of the colon, breast, lung, and kidney. (See <a href=\"topic.htm?path=pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy#H5\" class=\"medical medical_review\">&quot;Pathogenesis of the hypercoagulable state associated with malignancy&quot;, section on 'Cancer procoagulant'</a>.)</p><p>The mechanism by which APL leads to DIC, which is often accompanied by secondary fibrinolysis, is incompletely understood. Three tumor cell procoagulants may be of primary importance. (See <a href=\"topic.htm?path=pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy\" class=\"medical medical_review\">&quot;Pathogenesis of the hypercoagulable state associated with malignancy&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-promyelocytic-leukemia-in-adults#H5\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults&quot;, section on 'Coagulopathy and APL'</a>.) These are:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tissue factor, which forms a complex with factor VII to activate factors X and IX.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cancer procoagulant, which activates factor X independent of factor VII.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased annexin II receptor expression on the surface of the leukemic promyelocytes [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/67\" class=\"abstract_t\">67</a>]. Annexin II receptor binds plasminogen and its activator, tissue plasminogen activator, increasing plasmin formation by a factor of 60.</p><p/><p>The induction of tumor cell differentiation with retinoic acid can lead to rapid improvement in the coagulopathy. As an example, all-trans-retinoic acid (ATRA), used to treat APL, blocks transcription of the annexin II gene in leukemic promyelocytes, and reduces the incidence of severe DIC in this disorder [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/67\" class=\"abstract_t\">67</a>]. (See <a href=\"topic.htm?path=initial-treatment-of-acute-promyelocytic-leukemia-in-adults#H18\" class=\"medical medical_review\">&quot;Initial treatment of acute promyelocytic leukemia in adults&quot;, section on 'Control of coagulopathy'</a>.)</p><p>In patients with DIC, heparin administration remains controversial and of no proven benefit based on controlled clinical trials [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/68\" class=\"abstract_t\">68</a>]. Nevertheless, patients with clinically overt thromboembolic complications from DIC may benefit from heparin administration [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/57\" class=\"abstract_t\">57</a>]. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults#H28\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;, section on 'Prevention/treatment of thrombosis'</a>.)</p><p class=\"headingAnchor\" id=\"H516171\"><span class=\"h5\">Other TMAs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mechanisms of cancer-associated TMAs are less certain. It is presumed that direct endothelial injury is the initiating event in these settings [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/69,70\" class=\"abstract_t\">69,70</a>]. However, the onset of clinically evident disease may be delayed, frequently occurring months after chemotherapy has been discontinued or HCT has been performed [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/71-73\" class=\"abstract_t\">71-73</a>]. Affected patients typically present with slowly progressive renal failure, hypertension, and a relatively bland urine sediment, often occurring in the absence of clinically apparent tumor. (See <a href=\"topic.htm?path=pathophysiology-of-acquired-ttp-and-other-primary-thrombotic-microangiopathies-tmas\" class=\"medical medical_review\">&quot;Pathophysiology of acquired TTP and other primary thrombotic microangiopathies (TMAs)&quot;</a>.)</p><p>Management of MAHA requires identifying and focusing on treatment of the underlying cause [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/57\" class=\"abstract_t\">57</a>]. In patients receiving antineoplastic agents commonly associated with thrombotic microangiopathy (eg, <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a>, <a href=\"topic.htm?path=mitomycin-drug-information\" class=\"drug drug_general\">mitomycin</a>), careful monitoring for the early appearance of schistocytes and other manifestations of TMA is essential, since early discontinuation of the offending agent can be beneficial in curtailing progression [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/74\" class=\"abstract_t\">74</a>]. (See <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Anemia of inflammation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Certain cytokines (eg, interferon-alpha, interferon-beta, interferon-gamma, TNF-alpha, TGF-beta, IL-1, IL-6), produced in response to malignancy, may result in anemia by mediating a block in iron utilization, inhibiting erythropoietin mRNA synthesis, and exerting other ill-defined suppressive effects on erythropoiesis [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/75-79\" class=\"abstract_t\">75-79</a>]. IL-1, IL-6, and TNF-alpha induce increased levels of the iron-regulatory hormone hepcidin, which sequesters iron in macrophages, shunting iron away from erythropoiesis. In the case of Waldenstr&ouml;m macroglobulinemia (WM), the lymphoplasmacytic cells of WM produce hepcidin [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/80\" class=\"abstract_t\">80</a>]. Variously known as the &quot;anemia of chronic disease&quot; (ACD) or &quot;anemia of (chronic) inflammation,&quot; anemia due to inflammatory cytokines should be diagnosed after excluding other causes of anemia. (See <a href=\"topic.htm?path=anemia-of-chronic-disease-inflammation#H2\" class=\"medical medical_review\">&quot;Anemia of chronic disease/inflammation&quot;, section on 'Pathogenesis'</a>.)</p><p>While the anemia in ACD is most often normocytic and normochromic, careful review of peripheral blood smears will often reveal a small population of hypochromic microcytic RBCs. Other findings include the following. (See <a href=\"topic.htm?path=anemia-of-chronic-disease-inflammation#H686202\" class=\"medical medical_review\">&quot;Anemia of chronic disease/inflammation&quot;, section on 'Diagnosis'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abundant iron stores in bone marrow macrophages (unless concomitant blood loss has occurred) with decreased, if not absent, numbers of sideroblasts</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum erythropoietin levels that are inappropriately low given the degree of anemia and the presence of intact renal function</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low plasma concentrations of iron and total iron binding capacity (transferrin) in the presence of normal or increased plasma ferritin concentrations. A low ratio of the soluble transferrin receptor (sTfR) to the serum ferritin may help to distinguish ACD from iron deficiency. (See <a href=\"topic.htm?path=anemia-of-chronic-disease-inflammation#H685997\" class=\"medical medical_review\">&quot;Anemia of chronic disease/inflammation&quot;, section on 'sTfR - ferritin index'</a>.)</p><p/><p>Management involves treating the underlying disorder, although recombinant erythropoietin (EPO) administration may be of some benefit in certain patients with cancer [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/81\" class=\"abstract_t\">81</a>]. In this setting, measurement of the plasma EPO concentration may be helpful. Patients with ACD due to cancer who have EPO levels below 500 international <span class=\"nowrap\">units/mL</span> (although some authors suggest a cutoff of 100 <span class=\"nowrap\">mU/mL)</span> will frequently respond to the administration of recombinant human EPO. (See <a href=\"topic.htm?path=anemia-of-chronic-disease-inflammation#H17\" class=\"medical medical_review\">&quot;Anemia of chronic disease/inflammation&quot;, section on 'Treatment issues'</a>.)</p><p>Since availability of iron can limit hemoglobin response during treatment with erythropoiesis-stimulating agents (ESAs), use of ESAs requires iron monitoring and supplementation, often with intravenous iron preparations. (See <a href=\"topic.htm?path=role-of-erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-patients-with-cancer#H34\" class=\"medical medical_review\">&quot;Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer&quot;, section on 'Iron monitoring and supplementation'</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Pure red cell aplasia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>While a variety of drugs, chemicals, and non-malignant conditions may be responsible for the development of acquired pure red cell aplasia (PRCA), this profound hypoproliferative anemia, characterized by markedly decreased or absent erythroid progenitors in the bone marrow, marked reticulocytopenia, and normal leukocyte and platelet counts, can be a consequence of malignancy.</p><p>In older series, thymomas accounted for as many as 50 percent of PRCA cases, with the incidence of PRCA in patients with thymomas ranging from 1 to 15 percent [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/82-84\" class=\"abstract_t\">82-84</a>]. Subsequent series, however, implicate thymomas less frequently [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/85\" class=\"abstract_t\">85</a>]. Of the hematologic malignancies reported in association with PRCA, chronic lymphocytic leukemia (CLL) is one of the most frequently cited, with as many as 6 percent of CLL patients developing PRCA [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/86\" class=\"abstract_t\">86</a>]. Of these, two-thirds have B cell CLL and one-third have T cell CLL. However, in a Mayo Clinic series of 47 adults with acquired pure red blood cell aplasia, LGL leukemia was the most common underlying cause [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/87\" class=\"abstract_t\">87</a>]. (See <a href=\"topic.htm?path=acquired-pure-red-cell-aplasia-in-the-adult#H3\" class=\"medical medical_review\">&quot;Acquired pure red cell aplasia in the adult&quot;, section on 'Associated disorders'</a> and <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-large-granular-lymphocyte-leukemia#H113797909\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia&quot;, section on 'Autoimmune disorders'</a>.)</p><p>Other hematologic malignancies reported in association with PRCA include non-Hodgkin lymphomas, Hodgkin lymphoma, acute lymphoblastic leukemia, chronic myeloid leukemia, multiple myeloma, and primary myelofibrosis [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/88,89\" class=\"abstract_t\">88,89</a>]. While non-hematologic solid tumors have also been reported in association with PRCA, a cause-and-effect relationship between the patient's solid tumor and their PRCA has not been established in most cases [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/89\" class=\"abstract_t\">89</a>].</p><p>Mechanisms causing cancer-associated PRCA include [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/84,90-94\" class=\"abstract_t\">84,90-94</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunoglobulin inhibitors of erythropoietin responsive cells</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunoglobulin-mediated cytotoxicity directed against erythroblasts</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>T cell inhibition of erythropoietin-responsive cells</p><p/><p>Immunoglobulin inhibitors of erythropoietin have also been described; however, this mechanism as a cause of cancer-associated PRCA is much less common than mechanisms involving immunoglobulins directed against marrow erythroid cells [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/95\" class=\"abstract_t\">95</a>]. In PRCA associated with CLL, serum inhibitors of erythropoiesis have not been typically found. Rather, T lymphocytes appear to suppress erythroid growth in these patients, including those with B cell as well as T cell CLL [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/96,97\" class=\"abstract_t\">96,97</a>].</p><p>In patients receiving human recombinant erythropoietin, PRCA may rarely develop as a consequence of the production of antierythropoietin antibodies. (See <a href=\"topic.htm?path=pure-red-cell-aplasia-due-to-anti-erythropoietin-antibodies#H2\" class=\"medical medical_review\">&quot;Pure red cell aplasia due to anti-erythropoietin antibodies&quot;, section on 'Etiology and pathogenesis'</a>.)</p><p>In patients with thymoma-associated PRCA, resection of the thymoma has reversed the PRCA in 29 percent of cases and has improved the response rate to corticosteroids in others [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/83\" class=\"abstract_t\">83</a>]. In those whose thymomas are unresectable, radiotherapy may be beneficial [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/98\" class=\"abstract_t\">98</a>]. In patients with PRCA associated with other tumors, resection of the primary tumor may reverse the PRCA [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/99\" class=\"abstract_t\">99</a>]. In patients whose PRCA does not remit in response to treatment of their malignancy, immunosuppressive therapies may be required, including corticosteroids, <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, antithymocyte globulin, and cyclosporin [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/85,94,100-103\" class=\"abstract_t\">85,94,100-103</a>]. (See <a href=\"topic.htm?path=acquired-pure-red-cell-aplasia-in-the-adult#H20\" class=\"medical medical_review\">&quot;Acquired pure red cell aplasia in the adult&quot;, section on 'Management'</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Parvovirus B19 infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Now widely recognized as a cause of acquired PRCA, parvovirus B19, which selectively invades erythroid progenitors, can cause profound erythroid hypoplasia with erythroid maturation arrest, particularly with protracted infections arising in patients with altered immunity [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/104\" class=\"abstract_t\">104</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-parvovirus-b19-infection#H1295528480\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of parvovirus B19 infection&quot;, section on 'Chronic infection in immunosuppressed hosts'</a>.)</p><p>Since patients with cancer are often immunosuppressed, either primarily by their malignancy or secondarily by therapy for their disease [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/105\" class=\"abstract_t\">105</a>], parvovirus B19 infection must be considered as a possible cause of hypoproliferative anemia in such patients. In addition to profound erythroid hypoplasia with erythroid maturation arrest, a characteristic bone marrow finding in patients infected with parvovirus B19 is the presence of giant pronormoblasts with prominent eosinophilic intranuclear viral inclusions. Bone marrow biopsy can be highly informative in evaluating these patients (<a href=\"image.htm?imageKey=HEME%2F51435\" class=\"graphic graphic_picture graphicRef51435 \">picture 6</a>). (See <a href=\"topic.htm?path=acquired-pure-red-cell-aplasia-in-the-adult#H17\" class=\"medical medical_review\">&quot;Acquired pure red cell aplasia in the adult&quot;, section on 'Presentation'</a>.)</p><p>While high-dose immunoglobulin (IVIG) infusions are the treatment of choice in patients with protracted parvovirus B19 infection in the setting of altered immunity [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/106,107\" class=\"abstract_t\">106,107</a>], high-dose IVIG infusions may also be beneficial in patients with antibody-mediated PRCA [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/108\" class=\"abstract_t\">108</a>], including cases associated with hematologic malignancy [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/109\" class=\"abstract_t\">109</a>]. (See <a href=\"topic.htm?path=acquired-pure-red-cell-aplasia-in-the-adult#H20\" class=\"medical medical_review\">&quot;Acquired pure red cell aplasia in the adult&quot;, section on 'Management'</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">ANEMIA FROM EFFECTS OF CANCER TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most commonly, anemia in patients with cancer is the consequence of cancer therapy. Ionizing radiation, encompassing sites of marrow hematopoiesis, results in depletion of hematopoietic stem cells. However, systemic antineoplastic therapy contributes more to anemia development than radiotherapy [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/110,111\" class=\"abstract_t\">110,111</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stem cell death with long-term myelosuppression can occur following chemotherapy with non-cell-cycle-dependent drugs such as alkylators, often in a dose-dependent fashion.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Long-term myelodysplasia, often leading to acute myeloid leukemia, may be a consequence of the use of alkylating agents and inhibitors of topoisomerase II [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/111-113\" class=\"abstract_t\">111-113</a>]. (See <a href=\"topic.htm?path=therapy-related-myeloid-neoplasms-acute-myeloid-leukemia-and-myelodysplastic-syndrome#H6\" class=\"medical medical_review\">&quot;Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome&quot;, section on 'Cytotoxic agents that have been implicated'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of non-myeloablative doses of chemotherapy agents (ie, myelotoxic doses that do not require stem cell rescue) acting against actively proliferating cells (eg, <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, anthracyclines, <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a>, and <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">hydroxyurea</a>) leads to death of committed progenitor cells, invariably yielding early short-term myelosuppression. Although usually short term, treatment-related myelosuppression may worsen both in duration and severity as the number of treatment courses increases.</p><p/><p>Other mechanisms by which chemotherapy causes anemia include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Suppression of hematopoietic growth factor synthesis, especially erythropoietin [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/114\" class=\"abstract_t\">114</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oxidant damage to mature hematopoietic cells [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/115\" class=\"abstract_t\">115</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Induction of immune-mediated hematopoietic cell destruction (eg, <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>, <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a>, <a href=\"topic.htm?path=teniposide-drug-information\" class=\"drug drug_general\">teniposide</a>) (<a href=\"image.htm?imageKey=HEME%2F75322\" class=\"graphic graphic_table graphicRef75322 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/115-118\" class=\"abstract_t\">115-118</a>]. (See <a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-warm-agglutinins-and-drugs#H15\" class=\"medical medical_review\">&quot;Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs&quot;, section on 'Drug-related immune hemolysis'</a> and <a href=\"topic.htm?path=hemolytic-anemia-due-to-drugs-and-toxins#H253178517\" class=\"medical medical_review\">&quot;Hemolytic anemia due to drugs and toxins&quot;, section on 'Drug-related immune hemolysis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exacerbation of an underlying autoimmune hemolytic anemia associated with the patient's malignancy, as in <a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">fludarabine</a> treatment of chronic lymphocytic leukemia [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/51\" class=\"abstract_t\">51</a>]. (See <a href=\"#H13\" class=\"local\">'Autoimmune hemolytic anemia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Induction of microangiopathic hemolytic anemia, as in chemotherapy-induced thrombotic microangiopathy [<a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/74\" class=\"abstract_t\">74</a>]. (See <a href=\"#H516171\" class=\"local\">'Other TMAs'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute bone marrow stromal damage with intramedullary serofibrinous exudate and hemorrhage, particularly from high dose chemotherapy. (See <a href=\"topic.htm?path=evaluation-of-bone-marrow-aspirate-smears#H6\" class=\"medical medical_review\">&quot;Evaluation of bone marrow aspirate smears&quot;, section on 'Bone marrow necrosis'</a>.)</p><p/><p>Anemia may be &quot;apparent&quot; rather than real in patients with a normal RBC mass but an expanded plasma volume. This may be the result of fluid retention or volume expansion or the expanded plasma volume seen in patients with splenomegaly due to one of the myeloproliferative neoplasms. (See <a href=\"topic.htm?path=approach-to-the-adult-with-anemia#H2231503995\" class=\"medical medical_review\">&quot;Approach to the adult with anemia&quot;, section on 'Volume status'</a>.)</p><p>Management of symptomatic anemia from chemotherapy-induced myelosuppression includes transfusion of packed red blood cells <span class=\"nowrap\">and/or</span> the administration of recombinant erythropoietin or darbepoetin. Issues surrounding the use of ESAs, with or without iron supplementation, versus transfusion are discussed in detail separately. (See <a href=\"topic.htm?path=red-blood-cell-transfusion-in-adults-storage-specialized-modifications-and-infusion-parameters\" class=\"medical medical_review\">&quot;Red blood cell transfusion in adults: Storage, specialized modifications, and infusion parameters&quot;</a> and <a href=\"topic.htm?path=role-of-erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-patients-with-cancer\" class=\"medical medical_review\">&quot;Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1699283728\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-anemia-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Anemia in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics link (see <a href=\"topic.htm?path=anemia-of-chronic-disease-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Anemia of chronic disease (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H20\"><span class=\"h1\">SUMMARY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple factors may contribute to anemia in the cancer patient. It is important to correlate patients' clinical histories and physical exam findings with laboratory observations, since more than one contributing factor may be present. (See <a href=\"#H8168618\" class=\"local\">'Presence of multiple causes of anemia'</a> above.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>General mechanisms underlying the genesis of anemia &ndash; There are three general mechanisms for the development of anemia in any patient. One or more of these may be present in the anemic cancer patient:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Blood loss, both local and generalized</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Increased red blood cell destruction (hemolysis)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Decreased red blood cell production (bone marrow suppression)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mechanisms of anemia specific to the cancer patient &ndash; The following mechanisms for development of anemia in the cancer patient include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Direct effects of the neoplasm (eg, bleeding from the tumor, bone marrow replacement). (See <a href=\"#H3\" class=\"local\">'Anemia from direct effects of neoplasms'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Factors produced by the cancer cells (eg, autoantibodies, microangiopathy, amyloid production, cytokine inhibition of erythropoiesis). (See <a href=\"#H10\" class=\"local\">'Anemia from products of neoplasms'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Effects of cancer treatment (eg, suppression of erythropoiesis by radiation therapy <span class=\"nowrap\">and/or</span> chemotherapeutic agents). (See <a href=\"#H18\" class=\"local\">'Anemia from effects of cancer treatment'</a> above.)</p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/1\" class=\"nounderline abstract_t\">Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34:4.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/2\" class=\"nounderline abstract_t\">Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/3\" class=\"nounderline abstract_t\">Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/4\" class=\"nounderline abstract_t\">Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/5\" class=\"nounderline abstract_t\">Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93:1204.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/6\" class=\"nounderline abstract_t\">Escobar MA. Bleeding in the patient with a malignancy: is it an acquired factor VIII inhibitor? Cancer 2012; 118:312.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/7\" class=\"nounderline abstract_t\">Macci&ograve; A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 2015; 100:124.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/8\" class=\"nounderline abstract_t\">McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013; 39:534.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/9\" class=\"nounderline abstract_t\">Rodgers GM 3rd, Becker PS, Bennett CL, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2008; 6:536.</a></li><li class=\"breakAll\">United States FDA toxicity criteria, search under &quot;hemoglobim&quot; at: www.fda.gov/cder/cancer/toxicityframe.htm (Accessed on July 21, 2008).</li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/11\" class=\"nounderline abstract_t\">Reid TJ 3rd, Stamm CP, Dunning DM, Redmond J 3rd. Iron malabsorption in a patient with large cell lymphoma involving the duodenum. Am J Gastroenterol 1992; 87:1478.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/12\" class=\"nounderline abstract_t\">Dauth J, de Coning JP, Politzer WM, et al. Unusual presentation of multiple myeloma. A report of 2 cases. S Afr Med J 1984; 65:968.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/13\" class=\"nounderline abstract_t\">Sutton DR, Baird IM, Stewart JS, et al. Gastrointestinal iron losses in atrophic gastritis, postgastrectomy states and adult coeliac disease. Gut 1971; 12:869.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/14\" class=\"nounderline abstract_t\">Kimber C, Patterson JF, Weintraub LR. The pathogenesis of iron deficiency anemia following partial gastrectomy. A study of iron balance. JAMA 1967; 202:935.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/15\" class=\"nounderline abstract_t\">Schade SG, Cohen RJ, Conrad ME. Effect of hydrochloric acid on iron absorption. N Engl J Med 1968; 279:672.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/16\" class=\"nounderline abstract_t\">Ekenved G. Iron absorption studies. Studies on oral iron preparations using serum iron and different radioiron isotope techniques. Scand J Haematol Suppl 1976; 28:1.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/17\" class=\"nounderline abstract_t\">Dewar GA, Griffin SM, Ku KW, et al. Management of bleeding liver tumours in Hong Kong. Br J Surg 1991; 78:463.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/18\" class=\"nounderline abstract_t\">Srivastava DN, Gandhi D, Julka PK, Tandon RK. Gastrointestinal hemorrhage in hepatocellular carcinoma: management with transheptic arterioembolization. Abdom Imaging 2000; 25:380.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/19\" class=\"nounderline abstract_t\">Hayward SR, Lucas CE, Ledgerwood AM. Recurrent spontaneous intrahepatic hemorrhage from peliosis hepatis. Arch Surg 1991; 126:782.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/20\" class=\"nounderline abstract_t\">Cooperman AM, Weiland LH, Welch JS. Massive bleeding from a ruptured metastatic hepatic melanoma treated by hepatic lobectomy. Case report and review of the literature. Mayo Clin Proc 1976; 51:167.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/21\" class=\"nounderline abstract_t\">Autry JR, Weitzner S. Hemangiosarcoma of spleen with spontaneous rupture. Cancer 1975; 35:534.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/22\" class=\"nounderline abstract_t\">Margolin KA, Pak HY, Esensten ML, Doroshow JH. Hepatic metastasis in granulosa cell tumor of the ovary. Cancer 1985; 56:691.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/23\" class=\"nounderline abstract_t\">LITTON MA, LITTON EW, FOX TC. HEMORRHAGE FROM A GRANULOSA-THECA CELL TUMOR OF THE OVARY; (AN UNUSUAL CAUSE OF ACUTE ABDOMINAL PAIN IN A CHILD). Wis Med J 1965; 64:282.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/24\" class=\"nounderline abstract_t\">Witz M, Bernheim J, Dinbar A, Griffel B. Kidney fibroxanthoma (malignant fibrous xanthoma): a rare tumor and an unusual cause of retroperitoneal hemorrhage. J Surg Oncol 1984; 26:146.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/25\" class=\"nounderline abstract_t\">Witz M, Shpitz B, Dinbar A. Massive intraabdominal bleeding due to a retroperitoneal leiomyosarcoma. J Surg Oncol 1983; 24:132.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/26\" class=\"nounderline abstract_t\">Nguyen HT, Wolf JS Jr, Nash PA, et al. Acute retroperitoneal hemorrhage due to transitional cell carcinoma of the renal pelvis. J Urol 1995; 153:140.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/27\" class=\"nounderline abstract_t\">Swift DL, Lingeman JE, Baum WC. Spontaneous retroperitoneal hemorrhage: a diagnostic challenge. J Urol 1980; 123:577.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/28\" class=\"nounderline abstract_t\">Graham E, Cohen AW, Soulen M, Faye R. Symptomatic liver hemangioma with intra-tumor hemorrhage treated by angiography and embolization during pregnancy. Obstet Gynecol 1993; 81:813.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/29\" class=\"nounderline abstract_t\">Okazaki M, Higashihara H, Koganemaru F, et al. Intraperitoneal hemorrhage from hepatocellular carcinoma: emergency chemoembolization or embolization. Radiology 1991; 180:647.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/30\" class=\"nounderline abstract_t\">Gaffey MJ, Frierson HF Jr, Medeiros LJ, Weiss LM. The relationship of Epstein-Barr virus to infection-related (sporadic) and familial hemophagocytic syndrome and secondary (lymphoma-related) hemophagocytosis: an in situ hybridization study. Hum Pathol 1993; 24:657.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/31\" class=\"nounderline abstract_t\">Aung W, Koslosky W, Chin NW, Pincus MR. Diffuse large cell lymphoma of B-cell type associated with reactive hemophagocytosis. Ann Clin Lab Sci 1996; 26:433.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/32\" class=\"nounderline abstract_t\">Kobayashi Y, Uehara S, Inamori K, et al. Hemophagocytosis as a para-neoplastic syndrome in NK cell leukemia. Int J Hematol 1996; 64:135.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/33\" class=\"nounderline abstract_t\">Imashuku S, Hibi S, Sako M, et al. Hemophagocytosis by leukemic blasts in 7 acute myeloid leukemia cases with t(16;21)(p11;q22): common morphologic characteristics for this type of leukemia. Cancer 2000; 88:1970.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/34\" class=\"nounderline abstract_t\">Tsoi WC, Feng CS. Hemophagocytosis by rhabdomyosarcoma cells in bone marrow. Am J Hematol 1997; 54:340.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/35\" class=\"nounderline abstract_t\">Molad Y, Stark P, Prokocimer M, et al. Hemophagocytosis by small cell lung carcinoma. Am J Hematol 1991; 36:154.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/36\" class=\"nounderline abstract_t\">Conlan MG, Armitage JO, Bast M, Weisenburger DD. Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis. Cancer 1991; 67:1389.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/37\" class=\"nounderline abstract_t\">Rubins JM. The role of myelofibrosis in malignant leukoerythroblastosis. Cancer 1983; 51:308.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/38\" class=\"nounderline abstract_t\">Delsol G, Guiu-Godfrin B, Guiu M, et al. Leukoerythroblastosis and cancer frequency, prognosis, and physiopathologic significance. Cancer 1979; 44:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/39\" class=\"nounderline abstract_t\">O'Keane JC, Wolf BC, Neiman RS. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer 1989; 63:1539.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/40\" class=\"nounderline abstract_t\">Shamdas GJ, Ahmann FR, Matzner MB, Ritchie JM. Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 1993; 71:3594.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/41\" class=\"nounderline abstract_t\">Kavanaugh JH. Multiple myeloma, amyloid arthropathy, and pathological fracture of the femur: a case report. J Bone Joint Surg Am 1978; 60:135.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/42\" class=\"nounderline abstract_t\">Lanjewar DN, Raghuwanshi SR, Gupta D, et al. Systemic amyloidosis in Hodgkin's disease. Indian J Pathol Microbiol 1998; 41:169.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/43\" class=\"nounderline abstract_t\">P&eacute;rez Equiza E, Argui&ntilde;ano JM, Gastearena J. Successful treatment of AA amyloidosis secondary to Hodgkin's disease with 4'-iodo-4'-deoxydoxorubicin. Haematologica 1999; 84:93.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/44\" class=\"nounderline abstract_t\">Simmonds PD, Cottrell BJ, Mead GM, et al. Lymphadenopathy due to amyloid deposition in non-Hodgkin's lymphoma. Ann Oncol 1997; 8:267.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/45\" class=\"nounderline abstract_t\">Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstr&ouml;m's macroglobulinemia. J Clin Oncol 1993; 11:914.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/46\" class=\"nounderline abstract_t\">Coakley FV, Hricak H, Presti JC Jr, Small EJ. Diffuse retroperitoneal amyloidosis due to renal cell carcinoma. Br J Radiol 1999; 72:412.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/47\" class=\"nounderline abstract_t\">Delgado MA, Liu JY, Meleg-Smith S. Systemic amyloidosis associated with hepatocellular carcinoma. Case report and literature review. J La State Med Soc 1999; 151:474.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/48\" class=\"nounderline abstract_t\">Terrier B, Jaccard A, Harousseau JL, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine (Baltimore) 2008; 87:99.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/49\" class=\"nounderline abstract_t\">Spira MA, Lynch EC. Autoimmune hemolytic anemia and carcinoma: an unusual association. Am J Med 1979; 67:753.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/50\" class=\"nounderline abstract_t\">Engelfriet CP, Overbeeke MA, von dem Borne AE. Autoimmune hemolytic anemia. Semin Hematol 1992; 29:3.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/51\" class=\"nounderline abstract_t\">Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91:341.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/52\" class=\"nounderline abstract_t\">Gonzalez H, Leblond V, Azar N, et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 1998; 40:113.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/53\" class=\"nounderline abstract_t\">Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16:1885.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/54\" class=\"nounderline abstract_t\">Juliusson G. Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 1997; 39 Suppl 1:S41.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/55\" class=\"nounderline abstract_t\">Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998; 13:16.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/56\" class=\"nounderline abstract_t\">Lin YC, Chang HK, Sun CF, Shih LY. Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown primary origin. South Med J 1995; 88:683.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/57\" class=\"nounderline abstract_t\">Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341:586.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/58\" class=\"nounderline abstract_t\">Rytting M, Worth L, Jaffe N. Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am 1996; 10:365.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/59\" class=\"nounderline abstract_t\">Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986; 58:1428.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/60\" class=\"nounderline abstract_t\">Laffay DL, Tubbs RR, Valenzuela R, et al. Chronic glomerular microangiopathy and metastatic carcinoma. Hum Pathol 1979; 10:433.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/61\" class=\"nounderline abstract_t\">Lockhart AC. Microangiopathic haemolytic anaemia in metastatic malignancy. Hosp Med 2001; 62:244.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/62\" class=\"nounderline abstract_t\">Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2:209.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/63\" class=\"nounderline abstract_t\">Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007; 62:126.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/64\" class=\"nounderline abstract_t\">Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27:4834.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/65\" class=\"nounderline abstract_t\">Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8:5588.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/66\" class=\"nounderline abstract_t\">van der Poll T, B&uuml;ller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322:1622.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/67\" class=\"nounderline abstract_t\">Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340:994.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/68\" class=\"nounderline abstract_t\">Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982; 60:284.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/69\" class=\"nounderline abstract_t\">Groff JA, Kozak M, Boehmer JP, et al. Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis 1997; 29:280.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/70\" class=\"nounderline abstract_t\">Porta C, Danova M, Riccardi A, et al. Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 1999; 74:570.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/71\" class=\"nounderline abstract_t\">Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/72\" class=\"nounderline abstract_t\">Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001; 113:58.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/73\" class=\"nounderline abstract_t\">van der Lelie H, Baars JW, Rodenhuis S, et al. Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. Cancer 1995; 76:2338.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/74\" class=\"nounderline abstract_t\">Bruntsch U, Groos G, Tigges FJ, Gallmeier WM. Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients. Eur J Cancer Clin Oncol 1984; 20:905.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/75\" class=\"nounderline abstract_t\">Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/76\" class=\"nounderline abstract_t\">Means RT Jr. Advances in the anemia of chronic disease. Int J Hematol 1999; 70:7.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/77\" class=\"nounderline abstract_t\">Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008; 14:3262.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/78\" class=\"nounderline abstract_t\">Hohaus S, Massini G, Giachelia M, et al. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 2010; 28:2538.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/79\" class=\"nounderline abstract_t\">Falkensammer CE, Thurnher M, Leonhartsberger N, Ramoner R. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int 2011; 107:1893.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/80\" class=\"nounderline abstract_t\">Ciccarelli BT, Patterson CJ, Hunter ZR, et al. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenstr&ouml;m's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11:160.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/81\" class=\"nounderline abstract_t\">Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16:3412.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/82\" class=\"nounderline abstract_t\">JACOBS EM, HUTTER RV, POOL JL, LEY AB. Benign thymoma and selective erythroid aplasia of the bone marrow. Cancer 1959; 12:47.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/83\" class=\"nounderline abstract_t\">Hirst E, Robertson TI. The syndrome of thymoma and erythroblastopenic anemia. A review of 56 cases including 3 case reports. Medicine (Baltimore) 1967; 46:225.</a></li><li class=\"breakAll\">Dessypris EN. Pure Red Cell Aplasia, Johns Hopkins University Press, Baltimore 1988.</li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/85\" class=\"nounderline abstract_t\">Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood 1996; 87:4831.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/86\" class=\"nounderline abstract_t\">Chikkappa G, Zarrabi MH, Tsan MF. Pure red-cell aplasia in patients with chronic lymphocytic leukemia. Medicine (Baltimore) 1986; 65:339.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/87\" class=\"nounderline abstract_t\">Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996; 87:3000.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/88\" class=\"nounderline abstract_t\">Carloss HW, Saab GA, Tavassoli M. Pure red cell aplasia and lymphoma. JAMA 1979; 242:67.</a></li><li class=\"breakAll\">Krantz SB. Acquired pure red cell aplasia. In: Hematology: Basic Principles and Practice, 2nd ed, Hoffman R, Benz EJ, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 1995. p.350.</li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/90\" class=\"nounderline abstract_t\">Krantz SB. Pure red-cell aplasia. N Engl J Med 1974; 291:345.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/91\" class=\"nounderline abstract_t\">Abkowitz JL, Kadin ME, Powell JS, Adamson JW. Pure red cell aplasia: lymphocyte inhibition of erythropoiesis. Br J Haematol 1986; 63:59.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/92\" class=\"nounderline abstract_t\">Taniguchi S, Shibuya T, Morioka E, et al. Demonstration of three distinct immunological disorders on erythropoiesis in a patient with pure red cell aplasia and autoimmune haemolytic anaemia associated with thymoma. Br J Haematol 1988; 68:473.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/93\" class=\"nounderline abstract_t\">Masuda M, Arai Y, Okamura T, Mizoguchi H. Pure red cell aplasia with thymona: evidence of T-cell clonal disorder. Am J Hematol 1997; 54:324.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/94\" class=\"nounderline abstract_t\">Yamada O, Yun-Hua W, Motoji T, Mizoguchi H. Clonal T-cell proliferation causing pure red cell aplasia in chronic B-cell lymphocytic leukaemia: successful treatment with cyclosporine following in vitro abrogation of erythroid colony-suppressing activity. Br J Haematol 1998; 101:335.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/95\" class=\"nounderline abstract_t\">Peschle C, Marmont AM, Marone G, et al. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 1975; 30:411.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/96\" class=\"nounderline abstract_t\">Mangan KF, Chikkappa G, Scharfman WB, Desforges JF. Evidence for reduced erythroid burst (BFUE) promoting function of T lymphocytes in the pure red cell aplasia of chronic lymphocytic leukemia. Exp Hematol 1981; 9:489.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/97\" class=\"nounderline abstract_t\">Fujisao S, Tsuda H. Th1/Th2 balance alteration in the clinical course of a patient with pure red cell aplasia and thymoma. Br J Haematol 1998; 103:308.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/98\" class=\"nounderline abstract_t\">Penn CR, Hope-Stone HF. The role of radiotherapy in the management of malignant thymoma. Br J Surg 1972; 59:533.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/99\" class=\"nounderline abstract_t\">Gajwani B, Zinner EN. Pure red-cell aplasia. Associated with adenocarcinoma of stomach. N Y State J Med 1976; 76:2177.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/100\" class=\"nounderline abstract_t\">Zaentz SD, Krantz SB, Brown EB. Studies on pure red cell aplasia. Maintenance therapy with immunosuppressive drugs. Br J Haematol 1976; 32:47.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/101\" class=\"nounderline abstract_t\">Firkin FC, Maher D. Cytotoxic immunosuppressive drug treatment strategy in pure red cell aplasia. Eur J Haematol 1988; 41:212.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/102\" class=\"nounderline abstract_t\">Abkowitz JL, Powell JS, Nakamura JM, et al. Pure red cell aplasia: response to therapy with anti-thymocyte globulin. Am J Hematol 1986; 23:363.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/103\" class=\"nounderline abstract_t\">Kwong YL, Wong KF. Association of pure red cell aplasia with T large granular lymphocyte leukaemia. J Clin Pathol 1998; 51:672.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/104\" class=\"nounderline abstract_t\">Frickhofen N, Chen ZJ, Young NS, et al. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994; 87:818.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/105\" class=\"nounderline abstract_t\">Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96:1184.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/106\" class=\"nounderline abstract_t\">Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321:519.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/107\" class=\"nounderline abstract_t\">Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113:926.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/108\" class=\"nounderline abstract_t\">McGuire WA, Yang HH, Bruno E, et al. Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med 1987; 317:1004.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/109\" class=\"nounderline abstract_t\">Clauvel JP, Vainchenker W, Herrera A, et al. Treatment of pure red cell aplasia by high dose intravenous immunoglobulins. Br J Haematol 1983; 55:380.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/110\" class=\"nounderline abstract_t\">Asbell SO, Leon SA, Tester WJ, et al. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 1996; 29:243.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/111\" class=\"nounderline abstract_t\">Pedersen-Bjergaard J. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leuk Res 1992; 16:61.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/112\" class=\"nounderline abstract_t\">Cremin P, Flattery M, McCann SR, Daly PA. Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Ann Oncol 1996; 7:745.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/113\" class=\"nounderline abstract_t\">Sobecks RM, Le Beau MM, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23:1161.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/114\" class=\"nounderline abstract_t\">Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95:1650.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/115\" class=\"nounderline abstract_t\">Doll DC, Weiss RB. Hemolytic anemia associated with antineoplastic agents. Cancer Treat Rep 1985; 69:777.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/116\" class=\"nounderline abstract_t\">Marani TM, Trich MB, Armstrong KS, et al. Carboplatin-induced immune hemolytic anemia. Transfusion 1996; 36:1016.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/117\" class=\"nounderline abstract_t\">Habibi B. Drug induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias. Br J Haematol 1985; 61:139.</a></li><li><a href=\"https://www.uptodate.com/contents/hematologic-complications-of-malignancy-anemia-and-bleeding/abstract/118\" class=\"nounderline abstract_t\">Noronha V, Burtness B, Murren J, Duffy TP. Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature. Clin Colorectal Cancer 2005; 5:283.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7140 Version 24.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H20\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H8168494\" id=\"outline-link-H8168494\">OVERVIEW</a><ul><li><a href=\"#H8168638\" id=\"outline-link-H8168638\">Mechanisms</a></li><li><a href=\"#H8168787\" id=\"outline-link-H8168787\">Generalized bleeding</a></li><li><a href=\"#H8168618\" id=\"outline-link-H8168618\">Presence of multiple causes of anemia</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">WHO grading of anemia</a></li></ul></li><li><a href=\"#H3\" id=\"outline-link-H3\">ANEMIA FROM DIRECT EFFECTS OF NEOPLASMS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">External bleeding</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Impaired absorption of nutrients</a><ul><li><a href=\"#H13284596\" id=\"outline-link-H13284596\">- Iron deficiency</a></li><li><a href=\"#H13284602\" id=\"outline-link-H13284602\">- B12 deficiency</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">Internal bleeding</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Other causes of bleeding</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Hemophagocytosis</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Bone marrow replacement</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">ANEMIA FROM PRODUCTS OF NEOPLASMS</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">Amyloid</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Hemolysis</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">- Autoimmune hemolytic anemia</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Microangiopathic hemolysis</a><ul><li><a href=\"#H516159\" id=\"outline-link-H516159\">Mechanisms</a><ul><li><a href=\"#H516165\" id=\"outline-link-H516165\">- DIC</a></li><li><a href=\"#H516171\" id=\"outline-link-H516171\">- Other TMAs</a></li></ul></li></ul></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">Anemia of inflammation</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Pure red cell aplasia</a><ul><li><a href=\"#H17\" id=\"outline-link-H17\">- Parvovirus B19 infection</a></li></ul></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">ANEMIA FROM EFFECTS OF CANCER TREATMENT</a></li><li><a href=\"#H1699283728\" id=\"outline-link-H1699283728\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H116045599\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/7140|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/64267\" class=\"graphic graphic_picture\">- Blood smear, iron deficiency</a></li><li><a href=\"image.htm?imageKey=HEME/55274\" class=\"graphic graphic_picture\">- Tear drop cells</a></li><li><a href=\"image.htm?imageKey=HEME/68110\" class=\"graphic graphic_picture\">- Leukoerythroblastic blood smear</a></li><li><a href=\"image.htm?imageKey=HEME/70576\" class=\"graphic graphic_picture\">- Metastatic cancer marrow</a></li><li><a href=\"image.htm?imageKey=HEME/70611\" class=\"graphic graphic_picture\">- Spherocytes</a></li><li><a href=\"image.htm?imageKey=HEME/70851\" class=\"graphic graphic_picture\">- Schistocytes on peripheral smear</a></li><li><a href=\"image.htm?imageKey=HEME/51435\" class=\"graphic graphic_picture\">- Giant proerythroblast in PRCA</a></li></ul></li><li><div id=\"HEME/7140|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/57945\" class=\"graphic graphic_table\">- Performance status measure</a></li><li><a href=\"image.htm?imageKey=HEME/63831\" class=\"graphic graphic_table\">- Acute versus chronic DIC</a></li><li><a href=\"image.htm?imageKey=HEME/75322\" class=\"graphic graphic_table\">- Drugs immune hemolytic anemia</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-inhibitors-of-coagulation\" class=\"medical medical_review\">Acquired inhibitors of coagulation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-pure-red-cell-aplasia-in-the-adult\" class=\"medical medical_review\">Acquired pure red cell aplasia in the adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-von-willebrand-syndrome\" class=\"medical medical_review\">Acquired von Willebrand syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anemia-in-adults-due-to-decreased-red-blood-cell-production\" class=\"medical medical_review\">Anemia in adults due to decreased red blood cell production</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anemia-of-chronic-disease-inflammation\" class=\"medical medical_review\">Anemia of chronic disease/inflammation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-patient-with-a-bleeding-diathesis\" class=\"medical medical_review\">Approach to the adult patient with a bleeding diathesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-anemia\" class=\"medical medical_review\">Approach to the adult with anemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-suspected-ttp-hus-or-other-thrombotic-microangiopathy-tma\" class=\"medical medical_review\">Approach to the patient with suspected TTP, HUS, or other thrombotic microangiopathy (TMA)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-complications-following-purine-analog-therapy\" class=\"medical medical_review\">Autoimmune complications following purine analog therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cancer-related-fatigue-prevalence-screening-and-clinical-assessment\" class=\"medical medical_review\">Cancer-related fatigue: Prevalence, screening and clinical assessment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cancer-related-fatigue-treatment\" class=\"medical medical_review\">Cancer-related fatigue: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-and-diagnosis-of-iron-deficiency-and-iron-deficiency-anemia-in-adults\" class=\"medical medical_review\">Causes and diagnosis of iron deficiency and iron deficiency anemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-and-pathophysiology-of-vitamin-b12-and-folate-deficiencies\" class=\"medical medical_review\">Causes and pathophysiology of vitamin B12 and folate deficiencies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-and-pathophysiology-of-von-willebrand-disease\" class=\"medical medical_review\">Classification and pathophysiology of von Willebrand disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-hemophagocytic-lymphohistiocytosis\" class=\"medical medical_review\">Clinical features and diagnosis of hemophagocytic lymphohistiocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults\" class=\"medical medical_review\">Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-parvovirus-b19-infection\" class=\"medical medical_review\">Clinical manifestations and diagnosis of parvovirus B19 infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-primary-myelofibrosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of primary myelofibrosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-large-granular-lymphocyte-leukemia\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-promyelocytic-leukemia-in-adults\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-extranodal-nk-t-cell-lymphoma-nasal-type\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-subcutaneous-panniculitis-like-t-cell-lymphoma\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-laboratory-manifestations-and-diagnosis-of-immunoglobulin-light-chain-al-amyloidosis\" class=\"medical medical_review\">Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-hemolytic-anemia-in-the-adult\" class=\"medical medical_review\">Diagnosis of hemolytic anemia in the adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">Drug-induced thrombotic microangiopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-bone-marrow-aspirate-smears\" class=\"medical medical_review\">Evaluation of bone marrow aspirate smears</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-occult-gastrointestinal-bleeding\" class=\"medical medical_review\">Evaluation of occult gastrointestinal bleeding</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hemolytic-anemia-due-to-drugs-and-toxins\" class=\"medical medical_review\">Hemolytic anemia due to drugs and toxins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-acute-promyelocytic-leukemia-in-adults\" class=\"medical medical_review\">Initial treatment of acute promyelocytic leukemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-amyloidosis\" class=\"medical medical_review\">Overview of amyloidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-complications-of-chronic-lymphocytic-leukemia\" class=\"medical medical_review\">Overview of the complications of chronic lymphocytic leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-cold-agglutinin-disease\" class=\"medical medical_review\">Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-warm-agglutinins-and-drugs\" class=\"medical medical_review\">Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy\" class=\"medical medical_review\">Pathogenesis of the hypercoagulable state associated with malignancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-of-acquired-ttp-and-other-primary-thrombotic-microangiopathies-tmas\" class=\"medical medical_review\">Pathophysiology of acquired TTP and other primary thrombotic microangiopathies (TMAs)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anemia-of-chronic-disease-the-basics\" class=\"medical medical_basics\">Patient education: Anemia of chronic disease (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pure-red-cell-aplasia-due-to-anti-erythropoietin-antibodies\" class=\"medical medical_review\">Pure red cell aplasia due to anti-erythropoietin antibodies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=red-blood-cell-transfusion-in-adults-storage-specialized-modifications-and-infusion-parameters\" class=\"medical medical_review\">Red blood cell transfusion in adults: Storage, specialized modifications, and infusion parameters</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=regulation-of-iron-balance\" class=\"medical medical_review\">Regulation of iron balance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer\" class=\"medical medical_review\">Risk and prevention of venous thromboembolism in adults with cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-patients-with-cancer\" class=\"medical medical_review\">Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-anemia-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Anemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=therapy-related-myeloid-neoplasms-acute-myeloid-leukemia-and-myelodysplastic-syndrome\" class=\"medical medical_review\">Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-iron-deficiency-anemia-in-adults\" class=\"medical medical_review\">Treatment of iron deficiency anemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-venous-thromboembolism-in-patients-with-malignancy\" class=\"medical medical_review\">Treatment of venous thromboembolism in patients with malignancy</a></li></ul></div></div>","javascript":null}